| ★ FeaturedA Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)NCT05933577 detail · registry ↗Intismeran autogene (mRNA-4157 / V940), Moderna + Merck — INTerpath-001 adjuvant melanoma, Phase 3 | Merck Sharp & Dohme LLC+ ModernaTX, Inc. | Phase 3 | Active Not Recruiting | Melanoma | 2029-10-26 (est.) | 24 Sept 2025 |
| ★ FeaturedA Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)NCT06077760 detail · registry ↗Intismeran autogene (mRNA-4157 / V940), Moderna + Merck — INTerpath NSCLC, Phase 3 | Merck Sharp & Dohme LLC+ ModernaTX, Inc. | Phase 3 | Recruiting | Non-small Cell Lung Cancer | 2030-06-25 (est.) | 21 Aug 2026 |
| ★ FeaturedA Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDACNCT05968326 detail · registry ↗Autogene cevumeran (BNT122 / RO7198457), BioNTech + Genentech/Roche — adjuvant program | Genentech, Inc.+ BioNTech SE | Phase 2 | Recruiting | Adenocarcinoma, Pancreatic Ductal | 2031-01-01 (est.) | 2 Sept 2026 |
| ★ FeaturedAn Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)NCT03897881 detail · registry ↗Intismeran autogene (mRNA-4157 / V940), Moderna + Merck — KEYNOTE-942 randomized Phase 2b, adjuvant melanoma | ModernaTX, Inc.+ Merck Sharp & Dohme LLC | Phase 2 | Active Not Recruiting | Melanoma | 2032-11-30 (est.) | 3 Dec 2025 |
| ★ FeaturedA Clinical Trial Evaluating TG4050 in Head and Neck CancerNCT04183166 detail · registry ↗TG4050, Transgene + NEC — adjuvant head & neck cancer | Transgene | Phase 1/2 | Active Not Recruiting | Squamous Cell Carcinoma of Head and Neck | 2027-12-30 (est.) | 16 Jan 2026 |
| ★ FeaturedA Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic MelanomaNCT05309421 detail · registry ↗EVX-01, Evaxion Biotech — with pembrolizumab in advanced melanoma, Phase 2 | Evaxion Biotech A/S+ Merck Sharp & Dohme LLC | Phase 2 | Active Not Recruiting | Melanoma Stage IV, Unresectable Melanoma | 2025-09-30 (est.) | 22 Sept 2025 |
| ★ FeaturedNous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid TumorsNCT04041310 detail · registry ↗NOUS-209, Nouscom — microsatellite-unstable solid tumors, Phase 1/2 | Nouscom SRL+ Merck Sharp & Dohme LLC | Phase 1/2 | Active Not Recruiting | Solid Tumor, Adult | 2026-10-30 (est.) | 13 Feb 2026 |
| ★ FeaturedPersonalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBMNCT02287428 detail · registry ↗NeoVax personalized neoantigen peptide vaccine, Dana-Farber — with radiotherapy + pembrolizumab in newly diagnosed glioblastoma, Phase 1 | Dana-Farber Cancer Institute+ 4 | Phase 1 | Active Not Recruiting | Glioblastoma | 2027-02 (est.) | 17 Apr 2026 |
| ★ FeaturedGNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCCNCT04251117 detail · registry ↗GNOS-PV02, Geneos Therapeutics — with INO-9012 + pembrolizumab in advanced HCC, Phase 1/2 | Geneos Therapeutics | Phase 1/2 | Active Not Recruiting | HCC | 2024-11-29 | 22 Apr 2026 |
| Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCCNCT07722741 detail · registry ↗ | Geneos Therapeutics | Phase 2 | Recruiting | HCC | 2029-09 (est.) | 4 Sept 2026 |
| Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer PatientsNCT07300475 detail · registry ↗ | Washington University School of Medicine | Phase 1 | Not Yet Recruiting | Triple Negative Breast Cancer | 2030-07-31 (est.) | 4 Sept 2026 |
| Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesNCT06904066 detail · registry ↗ | National Cancer Institute (NCI) | Phase 1 | Recruiting | Malignancy, Hematologic, Neoplasms, Hematologic | 2029-04-30 (est.) | 4 Sept 2026 |
| Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 DiabetesNCT03929601 detail · registry ↗ | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)+ National Institutes of Health (NIH) | Phase 2 | Active Not Recruiting | Type 1 Diabetes Mellitus | 2027-03-31 (est.) | 1 Sept 2026 |
| EWSR1 Immunotherapy in Ewing Sarcoma and DSRCTNCT07695311 detail · registry ↗ | Rabi Hanna+ The Little Warriors Foundation | Phase 1 | Not Yet Recruiting | Ewing Sarcoma, Desmoplastic Small Round Cell Tumor | 2029-10 (est.) | 31 Aug 2026 |
| A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)NCT06623422 detail · registry ↗ | Merck Sharp & Dohme LLC+ ModernaTX, Inc. | Phase 3 | Recruiting | Carcinoma, Non-Small-Cell Lung | 2033-05-16 (est.) | 27 Aug 2026 |
| A Study Combining Personalized Neoantigen-based Dendritic Cell Vaccine With Microwave Ablation for the Treatment of Hepatocellular CarcinomaNCT03674073 detail · registry ↗ | Chinese PLA General Hospital+ Likang Life Sciences Holdings Limited | Phase 1 | Completed | Hepatocellular Carcinoma, Liver Cancer, Adult | 2020-10-15 | 27 Aug 2026 |
| Immune Modulatory DC Vaccine Against Brain TumorNCT03914768 detail · registry ↗ | Shenzhen Geno-Immune Medical Institute | Phase 1 | Not Yet Recruiting | Diffuse Intrinsic Pontine Glioma or Glioblastoma | 2029-05-31 (est.) | 26 Aug 2026 |
| A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)NCT07430202 detail · registry ↗ | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins+ 3 | Phase 1 | Not Yet Recruiting | Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC)) | 2030-09 (est.) | 25 Aug 2026 |
| Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary MalignanciesNCT04068194 detail · registry ↗ | National Cancer Institute (NCI) | Phase 1/2 | Active Not Recruiting | Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma | 2027-07-01 (est.) | 21 Aug 2026 |
| IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver CancerNCT03655002 detail · registry ↗ | City of Hope Medical Center+ National Cancer Institute (NCI) | Phase 1 | Active Not Recruiting | Recurrent Hepatocellular Carcinoma, Refractory Liver Carcinoma | 2027-03-02 (est.) | 21 Aug 2026 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsNCT05269381 detail · registry ↗ | Mayo Clinic | Phase 1/2 | Recruiting | Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | 2028-03-31 (est.) | 20 Aug 2026 |
| Preventive Dendritic Cell Vaccination for Lynch SyndromeNCT07412197 detail · registry ↗ | Radboud University Medical Center+ Dutch Cancer Society | Phase 1/2 | Not Yet Recruiting | Lynch Syndrome | 2029-12 (est.) | 19 Aug 2026 |
| Genomic Analysis to Identify a Predictive Biomarker for ImmunotherapyNCT03578185 detail · registry ↗ | Samsung Medical Center | — | Recruiting | Lung Cancer | 2030-12-31 (est.) | 12 Aug 2026 |
| Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerNCT03606967 detail · registry ↗ | National Cancer Institute (NCI) | Phase 2 | Recruiting | Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma | 2026-12-30 (est.) | 10 Aug 2026 |
| Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant MelanomaNCT07750067 detail · registry ↗ | Sun Yat-sen University | Phase 2 | Recruiting | Melanoma Metastatic, NRAS Mutation | 2030-07-28 (est.) | 10 Aug 2026 |
| Personalized Neoantigen-pulsed Autologous Dendritic Cell Injections for Malignant Solid TumorsNCT07752953 detail · registry ↗ | ZSky Biotech Inc | Phase NA | Recruiting | Advanced Solid Tumor, Cancer | 2029-08-10 (est.) | 7 Aug 2026 |
| An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid TumorsNCT07680582 detail · registry ↗ | Ruijin Hospital+ 2 | Phase EARLY_PHASE1 | Recruiting | Solid Tumor | 2028-06-30 (est.) | 3 Aug 2026 |
| Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III MeningiomaNCT03604978 detail · registry ↗ | National Cancer Institute (NCI) | Phase 1/2 | Active Not Recruiting | Grade 2 Meningioma, Grade 3 Meningioma | 2027-03-19 (est.) | 31 Jul 2026 |
| Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast CancerNCT02883062 detail · registry ↗ | National Cancer Institute (NCI) | Phase 2 | Active Not Recruiting | Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7 | 2019-12-18 | 31 Jul 2026 |
| Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRCNCT04912765 detail · registry ↗ | National Cancer Centre, Singapore+ Bristol-Myers Squibb | Phase 2 | Recruiting | Hepatocellular Carcinoma, Hepatocellular Cancer | 2026-12 (est.) | 31 Jul 2026 |
| Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic CancerNCT04117087 detail · registry ↗ | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins+ 3 | Phase 1 | Active Not Recruiting | Colorectal Cancer, Pancreatic Cancer | 2027-06-01 (est.) | 27 Jul 2026 |
| Personalized Neoantigen Cancer Vaccine for Patients With Solid TumorsNCT06614140 detail · registry ↗ | Seqker Biosciences, Inc. | Phase 1/2 | Completed | Cancer, Solid Tumor, Adult | 2025-08-15 | 24 Jul 2026 |
| Personalized Neoantigen Peptide Vaccines for Solid TumorsNCT07002203 detail · registry ↗ | Seqker Biosciences, Inc.+ Bumrungrad International Hospital | Phase 1/2 | Recruiting | Solid Tumors, Advanced Cancer | 2027-08 (est.) | 24 Jul 2026 |
| A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After SurgeryNCT07724106 detail · registry ↗ | West China Hospital | Phase 1 | Not Yet Recruiting | Ovarian Cancer, mRNA Vaccine | 2028-05-01 (est.) | 23 Jul 2026 |
| Intermediate-size IND for Treatment of Patients With Advanced Cancer Using T Cells Engineered to Express TCR Targeting Mutant KRASNCT07614048 detail · registry ↗ | Providence Health & Services | — | Available | PDAC - Pancreatic Ductal Adenocarcinoma, Colorectal Cancer | — | 23 Jul 2026 |
| Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerNCT05098210 detail · registry ↗ | Fred Hutchinson Cancer Center+ Amazon, Inc. | Phase 1 | Recruiting | Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | 2027-11-01 (est.) | 22 Jul 2026 |
| Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual DiseaseNCT06529822 detail · registry ↗ | Washington University School of Medicine+ Natera, Inc. | Phase 1 | Recruiting | Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma | 2030-01-31 (est.) | 17 Jul 2026 |
| Neoantigen Peptide Vaccine Plus Pembrolizumab in Renal Cell CarcinomaNCT07686744 detail · registry ↗ | Jian Lin | Phase 1 | Not Yet Recruiting | Renal Cell Carcinoma, Advanced | 2029-01-01 (est.) | 7 Jul 2026 |
| Safety, Tolerability, Immunogenicity, Pharmacodynamic Characteristics, and Preliminary Anti-tumor Activity of Personalized Cancer Vaccines Alone and in Combination With Toripalimab in Participants With Resected NSCLCNCT07683832 detail · registry ↗ | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School+ Suzhou Abogen Biosciences Co., Ltd. | Phase EARLY_PHASE1 | Not Yet Recruiting | Non-Small Cell Lung Cancer NSCLC | 2028-12-31 (est.) | 6 Jul 2026 |
| Pathologic and Immunologic Response After Ablative Radiation in Lung CancerNCT03603002 detail · registry ↗ | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase NA | Completed | Non-small Cell Lung Cancer Stage I | 2021-09-01 | 2 Jul 2026 |
| Exploratory Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247, Beijing YSCell Biotech Co., Ltd. [Abbreviated as YS])in Patients With Recurrent or Progressive GlioblastomaNCT07678138 detail · registry ↗ | Huanhu Hospital Affiliated to Tianjin Medical University | Phase NA | Not Yet Recruiting | Glioblastoma | 2027-11-30 (est.) | 1 Jul 2026 |
| RGL-270 + ICI in Advanced NSCLCNCT07652125 detail · registry ↗ | Guangdong Association of Clinical Trials+ Shanghai Regenelead Theraples,Co,Ltd. | Phase NA | Recruiting | NSCLC | 2027-12-31 (est.) | 30 Jun 2026 |
| Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic CancerNCT05013216 detail · registry ↗ | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins+ 2 | Phase 1 | Recruiting | High Risk Cancer, Pancreatic Cancer | 2027-10-01 (est.) | 30 Jun 2026 |
| A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With Ovarian Cancer After SurgeryNCT07676890 detail · registry ↗ | West China Hospital | Phase 1 | Not Yet Recruiting | Ovarian Cancer, mRNA Vaccine | 2028-05-30 (est.) | 30 Jun 2026 |
| Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas CancerNCT06205849 detail · registry ↗ | University of California, San Diego+ 2 | Phase 1 | Recruiting | Pancreatic Cancer | 2028-08 (est.) | 25 Jun 2026 |
| Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal CancerNCT02600949 detail · registry ↗ | M.D. Anderson Cancer Center+ National Cancer Institute (NCI) | Phase 1 | Enrolling By Invitation | Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | 2027-05-31 (est.) | 17 Jun 2026 |
| Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced SarcomaNCT07648069 detail · registry ↗ | Sun Yat-sen University | Phase 1 | Recruiting | Soft Tissue Sarcoma (STS), Osteosarcoma | 2026-12-31 (est.) | 15 Jun 2026 |
| BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid LeukemiaNCT04214249 detail · registry ↗ | National Cancer Institute (NCI) | Phase 2 | Active Not Recruiting | Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | 2024-11-27 | 12 Jun 2026 |
| 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCCNCT05317000 detail · registry ↗ | Barbara Burtness+ National Institute of Dental and Craniofacial Research (NIDCR) | Phase 2 | Recruiting | Squamous Cell Carcinoma of Head and Neck | 2028-06-30 (est.) | 10 Jun 2026 |
| Ex Vivo Expansion (ACT-X)NCT07137312 detail · registry ↗ | Mayo Clinic | — | Recruiting | Solid Tumor, Healthy | 2028-10-31 (est.) | 9 Jun 2026 |
| A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic TumorsNCT03289962 detail · registry ↗ | Genentech, Inc.+ BioNTech SE | Phase 1 | Completed | Melanoma, Non-Small Cell Lung Cancer | 2025-07-01 | 8 Jun 2026 |
| Expanded Access to PCNAT-01 for Patients With Resected Pancreatic Ductal Adenocarcinoma Following Surgical Resection and Adjuvant TherapyNCT07612930 detail · registry ↗ | Anda Biopharmaceutical Development (Shenzhen) Co., Ltd. | — | Available | Pancreatic Ductal Adenocarcinoma (PDAC) | — | 29 May 2026 |
| A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.NCT03219450 detail · registry ↗ | Dana-Farber Cancer Institute+ 3 | Phase 1 | Recruiting | Lymphocytic Leukemia | 2027-07-31 (est.) | 28 May 2026 |
| Preventive Dendritic Cell Vaccination for Lynch Syndrome CarriersNCT07609901 detail · registry ↗ | Radboud University Medical Center+ Dutch National Health Care Institute | Phase 3 | Not Yet Recruiting | Lynch Syndrome | 2032-10-01 (est.) | 27 May 2026 |
| Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast CancerNCT06631092 detail · registry ↗ | NEC Bio B.V+ NEC Bio Therapeutics | Phase 1/2 | Recruiting | Triple Negative Breast Cancer | 2027-12-31 (est.) | 26 May 2026 |
| To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid TumorsNCT07594964 detail · registry ↗ | Shenzhen Xinhe Biomedical | Phase 1 | Recruiting | Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Pancreatic Ductal Adenocarcinoma (PDAC) | 2029-10-30 (est.) | 19 May 2026 |
| A Study of DCTY1102 Injection in Participants With Advanced Solid TumorsNCT07014878 detail · registry ↗ | Beijing DCTY Biotech Co.,Ltd. | Phase 1 | Not Yet Recruiting | Colorectal Cancer, Lung Cancer | 2028-08 (est.) | 18 May 2026 |
| Nivolumab in Biochemically Recurrent dMMR Prostate CancerNCT04019964 detail · registry ↗ | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins+ Bristol-Myers Squibb | Phase 2 | Completed | Prostate Cancer, Recurrent Prostate Cancer | 2025-04-23 | 15 May 2026 |
| Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic CancerNCT07587827 detail · registry ↗ | Centre Georges Francois Leclerc | Phase 1 | Not Yet Recruiting | Metastatic Colorectal Cancer (CRC), Locally Advanced Colorectal Cancer | 2027-05-01 (est.) | 14 May 2026 |
| YS247 (Neoantigen-Pulsed DC Vaccine) for Metastatic Prostate CancerNCT07583160 detail · registry ↗ | Changhai Hospital | Phase 1 | Enrolling By Invitation | Metastatic Castration-Resistant Prostate Cancer Patients, Castration-Resistant Prostate Cancer (CRPC) | 2028-06-01 (est.) | 13 May 2026 |
| An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid TumorsNCT07583953 detail · registry ↗ | Suzhou Abogen Biosciences Co., Ltd.+ The First Affiliated Hospital of Soochow University | Phase EARLY_PHASE1 | Not Yet Recruiting | Solid Tumors | 2029-01-31 (est.) | 13 May 2026 |
| Safety and Tolerability of AI-Designed Pan-Cancer Neoantigen mRNA Vaccine (PAN-NeoVax) in Advanced Solid TumorsNCT07560943 detail · registry ↗ | West China Hospital | Phase 1 | Recruiting | Cancer | 2027-04-28 (est.) | 11 May 2026 |
| DC/MM Fusion Vaccine With BCMA CAR-T in R/R MMNCT07377435 detail · registry ↗ | David Avigan+ The V Foundation | Phase 1 | Recruiting | Multiple Myeloma, Refractory Multiple Myeloma | 2028-03-01 (est.) | 8 May 2026 |
| A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)NCT06295809 detail · registry ↗ | Merck Sharp & Dohme LLC+ ModernaTX, Inc. | Phase 2/3 | Terminated | Carcinoma, Squamous Cell, Skin Neoplasms | 2026-03-05 | 8 May 2026 |
| Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated GlioblastomaNCT04015700 detail · registry ↗ | Washington University School of Medicine+ 3 | Phase 1 | Active Not Recruiting | Glioblastoma | 2022-05-13 | 7 May 2026 |
| QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.NCT03552718 detail · registry ↗ | NantBioScience, Inc. | Phase 1 | Completed | Colorectal Cancer, Breast Cancer | 2025-03-18 | 7 May 2026 |
| A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple MyelomaNCT06799026 detail · registry ↗ | David Avigan+ Pfizer | Phase 1 | Recruiting | Multiple Myeloma, Relapse Multiple Myeloma | 2028-09-01 (est.) | 7 May 2026 |
| Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System TumorsNCT03988283 detail · registry ↗ | Washington University School of Medicine+ Children's Discovery Institute | Phase 1 | Recruiting | Pediatric Recurrent Central Nervous System Tumors | 2029-03-31 (est.) | 7 May 2026 |
| Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to SurgeryNCT05111353 detail · registry ↗ | Washington University School of Medicine+ 4 | Phase 1 | Completed | Pancreas Cancer, Pancreatic Cancer | 2025-11-03 | 6 May 2026 |
| Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated GlioblastomaNCT05743595 detail · registry ↗ | Washington University School of Medicine+ 3 | Phase 1 | Active Not Recruiting | Unmethylated Glioblastoma | 2026-04-07 | 4 May 2026 |
| Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After SurgeryNCT04968366 detail · registry ↗ | Beijing Tiantan Hospital+ ZhongSheng BioTech Inc. | Phase 1 | Completed | Glioblastoma Multiforme of Brain | 2024-04-30 | 4 May 2026 |
| Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance TherapyNCT07551037 detail · registry ↗ | Fujian Medical University Union Hospital | Phase 1 | Recruiting | Acute Myeloid Leukemia, Personalized Active Immunotherapy | 2026-09-01 (est.) | 1 May 2026 |
| Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With PembrolizumabNCT04266730 detail · registry ↗ | UNC Lineberger Comprehensive Cancer Center | Phase 1 | Suspended | Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer | 2027-06-01 (est.) | 23 Apr 2026 |
| Resistance Exercise Training to Improve Bone and Articular Cartilage Health in WomenNCT05889598 detail · registry ↗ | Loughborough University+ Versus Arthritis | Phase NA | Active Not Recruiting | Osteoporosis, Osteoarthritis | 2026-12-31 (est.) | 21 Apr 2026 |
| KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic CancerNCT07353645 detail · registry ↗ | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 1/2 | Recruiting | Colorectal Cancer, Pancreatic Cancer | 2029-01-01 (est.) | 15 Apr 2026 |
| Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)NCT06141369 detail · registry ↗ | Shanghai Jiao Tong University School of Medicine | Phase NA | Recruiting | Adrenal Cortical Carcinoma, Medullary Thyroid Cancer | 2026-12-30 (est.) | 9 Apr 2026 |
| A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid TumorNCT06682117 detail · registry ↗ | Fudan University | Phase NA | Recruiting | Treatment, Neoantigen | 2026-12-30 (est.) | 2 Apr 2026 |
| Personalized T-Cell Therapy iNeo-Vac-T01 in Advanced Colorectal CancerNCT07504523 detail · registry ↗ | Ying Yuan, MD+ Hangzhou Neoantigen Therapeutics Co., Ltd. | Phase 1 | Recruiting | Metastatic Colorectal Cancer (CRC) | 2027-12-31 (est.) | 1 Apr 2026 |
| Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant TherapyNCT06435351 detail · registry ↗ | H. Lee Moffitt Cancer Center and Research Institute | Phase EARLY_PHASE1 | Recruiting | Breast Cancer, Triple Negative Breast Cancer | 2029-05 (est.) | 1 Apr 2026 |
| Safety and Efficacy of Neoantigen-Based Personalized Immunotherapy as Consolidation Therapy After Standard Adjuvant Treatment in Resectable Stage III Colorectal Cancer or Non-Small Cell Lung CancerNCT07504484 detail · registry ↗ | Ying Yuan, MD+ Hangzhou Neoantigen Therapeutics Co., Ltd. | Phase 1 | Completed | CRC (Colorectal Cancer), Non Small Lung Cancer | 2023-12-31 | 31 Mar 2026 |
| A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical ResectionNCT07495215 detail · registry ↗ | Yinghua Xu | Phase 1/2 | Recruiting | Hepatocellular Carcinoma (HCC) | 2028-12-31 (est.) | 27 Mar 2026 |
| NeoVax + CDX-301 and Nivolumab or Pembrolizumab in MelanomaNCT04930783 detail · registry ↗ | Dana-Farber Cancer Institute+ Celldex Therapeutics | Phase 1 | Active Not Recruiting | Melanoma, Metastatic Melanoma | 2027-12-31 (est.) | 25 Mar 2026 |
| Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular LymphomaNCT03361852 detail · registry ↗ | Dana-Farber Cancer Institute | Phase 1 | Active Not Recruiting | Follicular Lymphoma | 2026-12-31 (est.) | 25 Mar 2026 |
| Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced CancersNCT03568058 detail · registry ↗ | Aaron Miller | Phase 1 | Completed | Advanced Cancer | 2022-12-12 | 24 Mar 2026 |
| rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMGNCT04943848 detail · registry ↗ | Ann & Robert H Lurie Children's Hospital of Chicago+ 3 | Phase 1 | Recruiting | Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant | 2026-09 (est.) | 17 Mar 2026 |
| A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian CancerNCT07455071 detail · registry ↗ | Peking University Third Hospital | Phase NA | Not Yet Recruiting | HRD-negative Epithelial Ovarian Cancer | 2027-09-30 (est.) | 16 Mar 2026 |
| Cancer Preventive Vaccine Nous-209 for Lynch Syndrome PatientsNCT05078866 detail · registry ↗ | National Cancer Institute (NCI) | Phase 1/2 | Active Not Recruiting | Colorectal Carcinoma, Lynch Syndrome | 2025-04-16 | 3 Mar 2026 |
| Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric CancerNCT07298200 detail · registry ↗ | Jia Wei+ NeoCura | Phase 1 | Recruiting | Advanced Gastric Cancer | 2028-06 (est.) | 25 Feb 2026 |
| A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic EngineeringNCT04426669 detail · registry ↗ | Intima Bioscience, Inc.+ Masonic Cancer Center, University of Minnesota | Phase 1/2 | Completed | Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms | 2025-05-28 | 23 Feb 2026 |
| A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric GliomaNCT06342908 detail · registry ↗ | Jonsson Comprehensive Cancer Center | Phase 1 | Active Not Recruiting | Diffuse Hemispheric Glioma, H3 G34-Mutant | 2027-03-08 (est.) | 17 Feb 2026 |
| XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic CancerNCT06353646 detail · registry ↗ | Wu Wenming+ NeoCura | Phase NA | Recruiting | Pancreatic Cancer | 2026-06 (est.) | 13 Feb 2026 |
| Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal CancerNCT07329894 detail · registry ↗ | Beijing GoBroad Hospital+ NeoCura | Phase 1 | Recruiting | Gastrointestinal Cancer | 2027-08 (est.) | 12 Feb 2026 |
| Evaluation of the Safety, Tolerability and Efficacy of iNeo-Vac-R01, an Individualized mRNA Therapeutic Technology Based on Tumor Neoantigens, for Adjuvant Treatment in Patients With Biliary Malignant Tumors After Radical ResectionNCT07368803 detail · registry ↗ | Yifan Wang+ Hangzhou Neoantigen Therapeutics Co., Ltd. | Phase 1/2 | Recruiting | Biliary Malignant Tumors | 2027-09-30 (est.) | 3 Feb 2026 |
| NeoVax Plus Ipilimumab in Renal Cell CarcinomaNCT02950766 detail · registry ↗ | Patrick Ott, MD, PhD+ 2 | Phase 1 | Active Not Recruiting | Kidney Cancer | 2027-12-31 (est.) | 3 Feb 2026 |
| Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell CarcinomaNCT03082534 detail · registry ↗ | University of California, San Diego+ Merck Sharp & Dohme LLC | Phase 2 | Completed | HNSCC, Lip SCC | 2025-07-21 | 28 Jan 2026 |
| Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed GlioblastomaNCT07365280 detail · registry ↗ | ZSky Biotech Inc | Phase 2 | Not Yet Recruiting | Glioblastoma | 2028-12-24 (est.) | 26 Jan 2026 |
| A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid TumorsNCT05741242 detail · registry ↗ | Jaime Leandro Foundation for Therapeutic Cancer Vaccines | Phase 1/2 | Enrolling By Invitation | Cancer, Solid Tumor | 2027-01 (est.) | 15 Jan 2026 |
| Expanded Access To Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid TumorsNCT06963697 detail · registry ↗ | Jaime Leandro Foundation for Therapeutic Cancer Vaccines | — | Available | Cancer | — | 15 Jan 2026 |
| Clinical Study of XP-006 mRNA Vaccine for R/R B-NHLNCT07334574 detail · registry ↗ | Ruijin Hospital+ Shanghai Xinpu BioTechnology Company Limited | Phase 1 | Not Yet Recruiting | B-cell Non-Hodgkin's Lymphoma (B-NHL) | 2028-01-01 (est.) | 13 Jan 2026 |
| COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal CancerNCT07328087 detail · registry ↗ | Biogenea Pharmaceuticals Ltd.+ Interbalkan Medical Center, Thessaloniki, Greece | Phase EARLY_PHASE1 | Recruiting | Colorectal Cancer Metastatic, Colorectal Cancer Stage III | 2030-12-02 (est.) | 9 Jan 2026 |
| Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid TumorsNCT06631079 detail · registry ↗ | NEC Bio B.V+ NEC Bio Therapeutics | Phase 1/2 | Active Not Recruiting | Solid Tumor | 2026-07-31 (est.) | 8 Jan 2026 |
| Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical StudyNCT07324473 detail · registry ↗ | First Affiliated Hospital of Chongqing Medical University | Phase 2 | Not Yet Recruiting | Hepatocellular Carcinomas, Resistance to Immunotherapy | 2028-01-01 (est.) | 7 Jan 2026 |
| Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With SurgeryNCT04161755 detail · registry ↗ | Memorial Sloan Kettering Cancer Center+ 2 | Phase 1 | Active Not Recruiting | Pancreatic Cancer | 2026-11-11 (est.) | 7 Jan 2026 |
| GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial CancerNCT07316361 detail · registry ↗ | Biogenea Pharmaceuticals Ltd. | Phase EARLY_PHASE1 | Enrolling By Invitation | Endometrial Carcinoma, Endometrial Carcinoma Stage III | 2029-12-02 (est.) | 7 Jan 2026 |
| Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced MelanomaNCT03929029 detail · registry ↗ | Dana-Farber Cancer Institute+ National Cancer Institute (NCI) | Phase 1 | Active Not Recruiting | Cutaneous Melanoma | 2022-12-27 | 5 Jan 2026 |
| A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in MelanomaNCT01970358 detail · registry ↗ | Patrick Ott, MD, PhD | Phase 1 | Completed | Melanoma | 2015-09 | 29 Dec 2025 |
| Evaluation of CYT-108, A Recombinant Protease Inhibitor, for Treatment of Mild To Moderate Primary Osteoarthritis Of The KneeNCT06263270 detail · registry ↗ | Cytonics Corporation | Phase 1 | Completed | Osteoarthritis, Knee, Osteoarthritis | 2025-03-15 | 26 Dec 2025 |